Overview
How Do I Manage Hypoglycemia Unawareness?
The Crisis of Unrecognized Severe Hypoglycemia: Get the Lowdown
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Dr. Lawrence Blonde presents a patient case and shares his personal approach used in clinical practice. He discusses how to manage hypoglycemia unawareness with a focus on diagnosis, reversing impaired awareness, and preparing patients.
This activity is intended for clinical endocrinologists, as well as NPs and PAs working with endocrinologists.
The purpose of this activity is to hear first-hand accounts from experts regarding recognition and management of hypoglycemia. This activity will review strategies to improve outcomes in the event of hypoglycemia, increase recognition of severe hypoglycemia, and improve guideline adherence. Upon completion of this activity, clinicians will be able to implement strategies for the prevention and treatment of severe hypoglycemic episodes.
Upon completion of this activity, participants will be able to:
• Identify barriers to recognizing and treating severe hypoglycemia
• Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
• Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes
• Identify barriers to recognizing and treating severe hypoglycemia
• Apply clinical guideline recommendations for prevention and treatment of severe hypoglycemia
• Introduce preemptive strategies to prepare patients/caregivers and improve outcomes in the event of severe hypoglycemic episodes
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Fran Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA
Director, Ochsner Diabetes Clinical Research Unit
Fran Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation; and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The following financial relationships have been provided:
Lawrence Blonde, MD, FACP, FACE
Sources of Funding for Research: Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi
Consulting Agreements: AstraZeneca, Gilead Sciences, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi
Speakers' Bureau: Janssen Pharmaceuticals, Inc., Novo Nordisk, and Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activities, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
